Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02143401 · ClinicalTrials.gov registry record · Phase 1
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT02143401: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT02143401 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02143401, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and the best dose of navitoclax when given together with sorafenib tosylate in treating patients with solid tumors that have returned (relapsed) or do not respond to treatment (refractory). Navitoclax and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Sorafenib
- OTHER Pharmacological Study
- BIOLOGICAL Navitoclax
- DRUG Sorafenib Tosylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2015-01-30 |
| Est. Completion | 2024-03-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02143401
The ClinicalTrials.gov registry entry for NCT02143401 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02143401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02143401 about?
NCT02143401 is a clinical study titled "Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors". This phase I trial studies the side effects and the best dose of navitoclax when given together with sorafenib tosylate in treating patients with solid tumors that have returned (relapsed) or do not respond to treatment (refractory). Navitoclax and sorafenib tosylate may stop the growth of tumor cel...
What is the current status of trial NCT02143401?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2015-01-30. Estimated completion is 2024-03-21.
What interventions are being tested in trial NCT02143401?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Sorafenib (DRUG), Pharmacological Study (OTHER), Navitoclax (BIOLOGICAL), Sorafenib Tosylate (DRUG).
Who is sponsoring clinical trial NCT02143401?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.